Australia markets close in 5 hours 45 minutes

Aptinyx Inc. (APTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.4992-0.0451 (-8.29%)
At close: 04:00PM EDT
0.5200 +0.02 (+4.17%)
After hours: 05:26PM EDT

Aptinyx Inc.

909 Davis Street
Suite 600
Evanston, IL 60201
United States
847 871 0377

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 40

Key executives

NameTitlePayExercisedYear born
Dr. Norbert G. RiedelExec. Chairman851.45kN/A1958
Dr. Andrew D. Kidd B.M. B.Ch., M.D.CEO, Pres & Director685.61kN/A1977
Mr. Ashish KhannaCFO & Chief Bus. Officer603.76kN/A1976
Mr. Juan EstupinanVP of Fin. & Accounting and ControllerN/AN/AN/A
Mr. Patrick FlavinSr. Mang. of Corp. Devel. & Investor RelationsN/AN/AN/A
Ms. Molly DirVP of HRN/AN/AN/A
Dr. Kathryn King Ph.D.Sr. VP of Clinical & CMC OperationsN/AN/AN/A
Dr. Harald Murck M.D., Ph.D.VP of Clinical & Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Corporate governance

Aptinyx Inc.’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.